APA (7th ed.) Citation

SA, I., K, P., J, K., C, P., KH, J., J, L., . . . IH, P. (2025). Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). ESMO open, 10(10), 105804. https://doi.org/10.1016/j.esmoop.2025.105804

Chicago Style (17th ed.) Citation

SA, Im, et al. "Genomic and Transcriptomic Analyses of Residual Invasive Triple-negative Breast Cancer After Neoadjuvant Chemotherapy in the Prospective MIRINAE Trial (a Randomized Phase II Trial of Adjuvant Atezolizumab Plus Capecitabine Compared to Capecitabine; KCSG-BR18-21)." ESMO Open 10, no. 10 (2025): 105804. https://doi.org/10.1016/j.esmoop.2025.105804.

MLA (9th ed.) Citation

SA, Im, et al. "Genomic and Transcriptomic Analyses of Residual Invasive Triple-negative Breast Cancer After Neoadjuvant Chemotherapy in the Prospective MIRINAE Trial (a Randomized Phase II Trial of Adjuvant Atezolizumab Plus Capecitabine Compared to Capecitabine; KCSG-BR18-21)." ESMO Open, vol. 10, no. 10, 2025, p. 105804, https://doi.org/10.1016/j.esmoop.2025.105804.